Ontario-based licensed cannabis producer FSD Pharma has announced the launch of a collaborative clinical research program in Israel through its strategic R&D partner, the Canadian–Israeli firm SciCann Therapeutics. SciCann Therapeutics develops and commercializes therapeutic products that target the endocannabinoid system.
The program will be established through SciCann’s partnership and collaboration agreement with Mor Research Applications, the technology transfer office and commercial arm of Clalit Healthcare Services, Israel’s largest medical insurance company and healthcare provider, a statement said.
Under the strategic alliance with Mor, FSD Pharma and SciCann will “execute a series of rigorous, randomized, placebo-controlled clinical studies” to demonstrate safety and efficacy, in order to “bring to market advanced and innovative cannabinoid-based products.”
FSD Pharma has already secured exclusive licensing rights for the manufacturing and distribution of SciCann’s line of patent-pending, cannabinoid-based products in Canada.
“The launch of this clinical study collaboration program in Israel further demonstrates our focus and commitment to bringing disruptive science-based cannabinoid therapies to Canadian patients, and provide them with innovative cannabis products that have been tested and verified in rigorous clinical studies for the highest level of safety and efficacy,” Zeeshan Saeed, EVP and Director of FSD Pharma, said.